NeoGenomics Announces Pricing of $148 Million Offering

NeoGenomics, Inc. (NASDAQ: NEO),  a leading provider of cancer-focused genetic testing services, announced on 5/22/19 the pricing of its underwritten public offering of 7,000,000 shares of its common stock at a public offering price of $21.25 per share. Gross proceeds to NeoGenomics from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by NeoGenomics, are expected to be $148,750,000.